Journal article
Engineering genome-free bacterial cells for effective SARS-COV-2 neutralisation
- Abstract:
- The COVID-19 pandemic has caused unparalleled impacts on global social dynamics, healthcare systems and economies, highlighting the urgent need for effective interventions to address current challenges and future pandemic preparedness. This study introduces a novel virus neutralisation platform based on SimCells (~1 μm) and mini-SimCells (100-200 nm), which are chromosome-free and non-replicating bacteria from an LPS-free Escherichia coli strain (ClearColi). SimCells and mini-SimCells were engineered to display nanobodies on their surface, specifically targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein - a critical immunogenic fragment essential for viral entry into host cells. It was demonstrated that nanobody-expressing SimCells achieved over 90% blocking efficiency against synthesised RBD from both the original Wuhan and the B.1.351 (Beta) variant using competitive enzyme-linked immunosorbent assay (ELISA) assay. More importantly, live virus neutralisation assays demonstrated that NB6 nanobody-presenting mini-SimCells effectively neutralised the live SARS-CoV-2 Victoria variant with an IC50 of 2.95 × 109 ± 1.40 × 108 mini-SimCells/mL. Similarly, VE nanobody-presenting mini-SimCells effectively neutralised the B.1.351 (Beta) variant of the SARS-CoV-2 virus with an IC50 of 5.68 × 109 ± 9.94 × 108 mini-SimCells/mL. The mini-SimCells successfully protected Vero cells, a cell line derived from the kidney of an African green monkey, from infection by the live virus of SARS-CoV-2 and its variants. These results suggest that SimCell-based neutralisation offers a promising strategy for the prevention and treatment of SARS-CoV-2, and potentially other viral infections.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Supplementary materials, pdf, 485.7KB, Terms of use)
-
(Preview, Version of record, pdf, 2.5MB, Terms of use)
-
- Publisher copy:
- 10.1111/1751-7915.70109
Authors
+ Engineering and Physical Sciences Research Council
More from this funder
- Funder identifier:
- https://ror.org/0439y7842
- Grant:
- EP/M002403/1
- Publisher:
- Wiley
- Journal:
- Microbial Biotechnology More from this journal
- Volume:
- 18
- Issue:
- 3
- Article number:
- e70109
- Place of publication:
- United States
- Publication date:
- 2025-03-05
- Acceptance date:
- 2025-01-30
- DOI:
- EISSN:
-
1751-7915
- Pmid:
-
40042439
- Language:
-
English
- Keywords:
- Pubs id:
-
2094267
- Local pid:
-
pubs:2094267
- Deposit date:
-
2025-04-24
- ARK identifier:
Terms of use
- Copyright holder:
- Yin et al.
- Copyright date:
- 2025
- Rights statement:
- © 2025 The Author(s). Microbial Biotechnology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work isproperly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record